- Home
- Daily Diary
- Asset Class
- Sector
- Latest
- Author
- Street Notes
- TheStreet
- Switch to
- Premium Tools
- Real Money
- Real Money Pro
- Action Alerts PLUS
- Stocks Under $10
- Breakout Stocks
- Options Profits
Latest Commentary
Real Money: Independent market insight from a veteran team of trusted Wall Street pros.
• Up-to-the-minute reports on market activity
• Actionable trade ideas
• Up-to-the-minute reports on market activity
• Actionable trade ideas
Latest Strategies
Real Money Pro: Professional tools and specific trade ideas for active investors.
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
• Information-packed market flow providing trade ideas, fast
• Dynamic interface with professional-grade analytical tools
• Full, unlimited access to Real Money
Latest Alert
May 22, 2013 | 03:18 PM EDT
The company renews its commitment to return cash to shareholders. FULL ALERT »
Action Alerts PLUS: Jim Cramer and Stephanie Link actively manage a real money portfolio for Jim's charitable trust.
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
• Timely trade alerts including price targets
• Unique insight into market movements
• Guidance on how to trade right alongside Jim and Stephanie
Latest Alert
May 22, 2013 | 10:27 AM EDT
The stock has doubled over the past three months and we don't want to be greedy with our gains. FULL ALERT »
Stocks Under $10: David Peltier manages a portfolio of affordable stocks with huge upside potential.
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
• Identify fast-growing small-cap stock opportunities
• Buy and sell alerts allow you to analyze overlooked opportunities quickly
• In-depth reports and research packed with proprietary analysis
Latest Alert
May 22, 2013 | 02:54 PM EDT
We are advantage of the market weakness to buy more shares of this holding. We are also bumping up our rating on the stock. FULL ALERT »
Breakout Stocks: Bryan Ashenberg, CFA, manages a portfolio of small and mid-cap stocks with high growth potential.
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
• Identify industry-changing macrotrends in their infancy
• Timely trade alerts loaded with detailed research
• Frequent communication about all Bryan's portfolio holdings
Latest Commentary
Options Profits: Day in and day out, our team of professional options traders search for inventive plays for trading spikes in market activity, emerging trends, and breaking news and events. These veterans reveal all their charts and technical data — delivering daily strategies and insightful commentary written specifically for the options trader plus 40 options trade ideas per week!
Celgene Corporation (CELG)
CELG (NASDAQ:Drugs)
$123.44
-0.06
-0.05%
Today's Range: 122.56 - 128.35 |
CELG Avg Daily Volume: 3,210,400
| Last Update: 05/22/13 - 4:00 PM EDT |
| Volume: 4,199,827 |
| YTD Performance: 57.39% |
| Open: $124.11 |
| Previous Close: $123.50 |
| 52 Week Range: $58.53 - $131.82 |
| Oustanding Shares: 417,122,477 |
| Market Cap: 51,514,625,910 |
Analysts Ratings
| Historical Rec | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago |
|---|---|---|---|---|
| Strong Buy | 19 | 21 | 21 | 21 |
| Moderate Buy | 2 | 2 | 2 | 2 |
| Hold | 4 | 3 | 4 | 4 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.40 | 1.29 | 1.35 | 1.35 |
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Average Earnings Estimates
| Qtr (06/13) | Qtr (09/13) | FY (12/13) | FY (12/14) | |
|---|---|---|---|---|
| Average Estimate | $1.31 | $1.29 | $5.34 | $6.50 |
| Number of Analysts | 4 | 4 | 4 | 4 |
| High Estimate | $1.36 | $1.37 | $5.59 | $7.09 |
| Low Estimate | $1.25 | $1.26 | $5.14 | $6.15 |
| Prior Year | $1.12 | $1.19 | $4.50 | $5.34 |
| Growth Rate (Year over Year) | 16.74% | 8.61% | 18.61% | 21.73% |
pharmamaven: Bernstein put out a 109 page report praising upside to ests for $CELG Pomalyst & Revlimid. Up $5 then mkt tanked. Expect strong run Thurs.
9 hours ago from web
9 hours ago from web
thebscott: @awalsh04 $CELG is at a key level tug o war going on. I like downside r/r especially if spy keeps cracking.
15 hours ago from Twitter for iPad
15 hours ago from Twitter for iPad
thebscott: The ugly - $EW (closed position quickly lol) $FLEX calls $VRML short (unreal) $CELG short closed out way early
15 hours ago from Twitter for iPad
15 hours ago from Twitter for iPad
getbillasap: @getbillasap Earlier today I tweeted "out $affy 120 weeklies 6.5 from 5.6". meant $celg. I bet Iam the 1st person in history to confuse them
16 hours ago from web
16 hours ago from web
getbillasap: bot $celg weekly 120 calls at 3.9. Taking profits from the earlier trade today. Super risky
17 hours ago from web
17 hours ago from web
alphavolume: $CELG Bought at 126.25 with stop < 125. That's 1% risk. No big deal. Good volume today at open. Big $ wants in and they'll defend.
19 hours ago from StockTwits Web
19 hours ago from StockTwits Web
These two names have been earnings leaders, and well worth putting on your watch list.
Celgene downgraded at Oppenheimer
Shares of CELG downgraded to Perform from Outperform, Oppenheimer said. Concerns about future acquisitions.
Celgene downgraded at Piper
CELG was downgraded from Overweight to Neutral, Piper Jaffray said. $86 price target. Company lacks near-term catalysts.
Celgene target raised at Jefferies
Shares of CELG now seen reaching $91, Jefferies said. Positive topline data for Abraxane. Buy rating.
Celgene downgraded at UBS
CELG was downgraded from Buy to Neutral, UBS said. $80 price target. Valuation call, as the stock is up 27% since Revlimid was not approved in the EU.
Celgene target boosted at BMO
Shares of CELG now seen reaching $90, according to BMO Capital. Revlimid patents should hold up well against generic challenges. Outperform rating.
Celgene numbers raised at Jefferies
Shares of CELG now seen reaching $81, Jefferies said. Estimates also raised on Myeloma survey. Buy rating.
Let's what's happened to the stock since reaching its newest low.
Dan Fitzpatrick examines three stocks viewed onFast Money. Today's stocks include Amgen, Gilead, and Celgene.
They remind me of the old-line pharma companies in their formative years.
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.
IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.
© 2013 TheStreet, Inc. All rights reserved.